What You Need to Know About Incyte Corporation's Q2 Earnings
Incyte Corporation's fiscal Q2 earnings report was released on Tuesday, April 28. Let's dive in to see if (INCY) missed or beat analyst's expectations.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company’s clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Commentary & Analysis
Which Is a Better Investment, Incyte Corporation or Avidity Biosciences, Inc. Stock?
Learn more about whether Incyte Corporation or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Which Is a Better Investment, Ascendis Pharma A/S or Incyte Corporation Stock?
Learn more about whether Ascendis Pharma A/S or Incyte Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Why Incyte Corporation’s (INCY) Stock Is Down 5.66%
As of Tuesday, February 10, Incyte Corporation’s INCY share price has dipped by 5.66%, which has investors questioning if this is right time to buy.Jenna Brashear
What You Need to Know About Incyte Corporation's Q1 Earnings
Incyte Corporation's fiscal Q1 earnings report was released on Tuesday, February 10. Let's dive in to see if (INCY) missed or beat analyst's expectations.Jenna Brashear
Financial Summary
| Share Statistics | INCY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $24,226.4 | $252.6 | 88% |
|
| Shares Out (Mil) | 208.2 | 52.3 | 77% |
|
| Institutional Ownership | 99.5% | 92.1% | 89% |
|
| Float (Mil) | 170.4 | 40.2 | 71% |
|
| Beta | 0.76 | 0.95 | 44% |
|
| Avg Daily Volume (000s) | 2,235 | 455 | 84% |
|
| Price Change (52-week) |
54.1% | 52.9% | 82% |
|
| Growth | INCY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 14.0% | 13.6% | 70% |
|
| Net Income (5yr) | 44.7% | (9.9%) | 92% |
|
| EPS (5yr) | 46.3% | 16.0% | 91 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 47.3% | (15.6%) | 93% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 13 | 15 | 18 | |
| Current EPS | ($3.433) | $3.521 | $8.788 | |
| Month Ago EPS | $1.482 | $7.730 | $9.313 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | $2.021 | $7.715 | $9.058 | |
| Year/Year Chg | (222.2%) | (45.1%) | 45.0% | |
| Financials | INCY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5,820 | $38 | 77% |
|
| Net Income (TTM) (Mil) | $1,612 | ($43) | 91% |
|
| EPS (TTM) | $8.135 | ($1.600) | 92% |
|
| Operating Cash Flow (TTM) (Mil) | $1,980 | ($31) | 88% |
|
| Net Cash Flow (TTM) (Mil) | $2,027 | $5 | 97% |
|
| Long-Term Debt (Q1) (Mil) | $28 | $5 | 35% |
|
| Enterprise Value (Q1) (Mil) | $21,265 | $180 | 84% |
|
| Valuation | INCY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.79 | 2.56 | 72% |
|
| P/E | 15.2 | 19.0 | 37% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.3 | 0.9 | 14% |
|
| Ratios | INCY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 55.7% | 63.8% | 68% |
|
| Net Margin | 27.7% | (67.3%) | 87% |
|
| ROA | 23.5% | (49.8%) | 97% |
|
| ROE | 30.7% | (55.5%) | 88% |
|
| Liabilities to Assets | 19.4% | 30.3% | 12% |
|
| F-Score | 7 | 3 | 84% |
|
Passing Stock Screens
As of 7/31/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Price-to-Sales Screen
Factors: Value, Growth
Research indicates that using price-to-sales ratios may lead to better investment results than price-to-book-value ratios or price-earnings ratios.
| Performance Since Inception: | 13.0% |
| +/- S&P 500: | +5.5 |
FACTOR STRATEGY
Return on Equity Screen
Factors: Quality, Growth
A screen that identifies stocks with above average earnings and sales growth that have consistently outperformed their peers measured by ROE.
| Performance Since Inception: | 13.1% |
| +/- S&P 500: | +5.6 |
FACTOR STRATEGY
Value on the Move--PEG With Hist Growth Screen
Factors: Value, Quality, Momentum, Growth
Using PEG ratios and price strength to find growth stocks trading at a reasonable price.
| Performance Since Inception: | 13.9% |
| +/- S&P 500: | +6.4 |
